On September 24, Eli Lilly and the Food and Drug Administration (FDA) will begin oral arguments before the 7th Circuit Court of Appeals in Eli Lilly and Company v. Robert F. Kennedy, Jr. Officially, the case is about a narrow technical question: Is Eli Lilly's experimental weight loss treatment retatrutide a biologic product or a conventional drug?
But it's actually about the legal and bureaucratic gymnastics Lilly is performing to protect its upcoming peptide from molecular copycats and how affordability will likely suffer if it succeeds.
